title: [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].
abstract: Chronic infections by hepatitis B (HBV) and C virus (HCV) result in diagnosis and therapeutic issues in dialysis and kidney recipients patients. The exposure to nosocomial, including blood transfusion, risk explains the high prevalence of HBV and HCV infection in this setting. Chronic infection reduces the survival of both patients and allografts, including a specific risk of de novo glomerulonephritis. Cirrhosis was considered as a contra-indication to renal transplantation given the high risk of decompensation and death, questionning the indication of a combined liver and kidney transplantation. Thus, it is mandatory to screen HBV and HCV markers in all dialysis patients, whether or not they are candidates to transplantation. Liver biopsy allows evaluating the severity of the liver disease since the noninvasive markers of fibrosis appear to be less accurate in "renal" patients than in the general population and to better define antiviral therapeutic indications. HCV treatment was mainly based on pegylated interferon α (and low doses of ribavirin), which is contra-indicated in kidney recipients given the risk of graft rejection; HCV treatment is now based on the use of oral direct acting antivirals, which are very potent and well tolerated. HBV replication is now easily suppressed by second-generation nucleos(t)tidic analogues (entecavir and tenofovir), which will be indicated in all the dialysis patients with significant fibrosis (F2,3 or 4 according to the Metavir scoring system) and in any candidate to renal transplantation and to any HBsAg-positive kidney recipients. The best treatment remains preventive by anti-HBV vaccination for HBV and by the respect of universal hygiene rules for HCV.
authors.affiliation: Unité d'hépatologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Inserm U 1016, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
authors.forename: Anaïs
authors.initials: A
authors.lastname: Vallet-Pichard
authors.affiliation: Unité d'hépatologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Inserm U 1016, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: stanislas.pol@cch.aphp.fr.
authors.forename: Stanislas
authors.initials: S
authors.lastname: Pol
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D000075202:Contraindications; D016174:Hepacivirus; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006515:Hepatitis B virus; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000628:therapy / Q000821:virology*; D016030:Kidney Transplantation / Q000379:methods; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: Dialysis; Hepatitis B virus; Hepatitis C virus; Hépatites virales; Renal transplantation; Transplantation rénale; Viral hepatitis; Virus de l’hépatite B; Virus de l’hépatite C; Épuration extrarénale